Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Core Insights - Revolution Medicines, Inc. reported significant clinical advancements in its RAS(ON) inhibitors portfolio, particularly focusing on daraxonrasib and zoldonrasib for RAS-addicted cancers, with pivotal data expected in 2026 [2][5][6] Clinical Progress - The company is advancing daraxonrasib in three Phase 3 studies for pancreatic ductal adenocarcinoma (PDAC) and has shown promising results in combination therapies [3][4] - Zoldonrasib has demonstrated a favorable safety profile and is being evaluated in various combinations, with initial data showing a 63% partial response rate in patients with metastatic PDAC [4][5] - The company plans to initiate multiple Phase 3 trials in 2026, including RASolve 308 for zoldonrasib in NSCLC [9][10] Financial Performance - As of December 31, 2025, the company reported cash and marketable securities of $2.0 billion, including a $250 million royalty monetization tranche [19] - Research and development expenses for Q4 2025 were $294.9 million, up from $188.1 million in Q4 2024, primarily due to increased clinical trial costs [20] - The net loss for the full year 2025 was $1.1 billion, compared to a net loss of $600.1 million in 2024, reflecting higher operational costs [25] Future Guidance - The company anticipates full-year 2026 GAAP operating expenses to be between $1.6 billion and $1.7 billion, including estimated non-cash stock-based compensation of $180 to $200 million [26]